insights_auto
Zašto je 8NE pao 12,70%?
Istražite detaljnijechevron_right
8NE:FRA
Lisata Therapeutics, Inc.
0,82 €
arrow_downward
−12,70%(−0,12) 1D
12. lis, 08:21:59 GMT+2 · EUR
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za 8NE...
Otvori
0,82 €
Najviša
0,82 €
Najniža
0,82 €
Trž. kap.
11,45 mil.
Prosj. kol.
0,00
Količina
0,00
52-tjed. najviša
4,34 €
52-tjed. najniža
0,74 €
Broj djelatnika
21
Otvori
0,82 €
Najviša
0,82 €
Najniža
0,82 €
Trž. kap.
11,45 mil.
Prosj. kol.
0,00
Količina
0,00
52-tjed. najviša
4,34 €
52-tjed. najniža
0,74 €
Broj djelatnika
21
Vijesti
Iz web-izvora i od partnera za vijesti
https://www.dars.gov.et/
·
prije 1 tjedan
LSTA Q3 2025 Earnings: Narrower-Than-Expected Loss as Clinical-Stage Biotech Beats EPS Estimate - Earnings Manipulation Risk
https://www.dars.gov.et/
·
prije 2 mjeseca
LSTA Q3 2025 Earnings: Narrower-than-Expected Loss as Clinical Progress Continues - Estimate Uncertainty
Profil
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Lisata Therapeutics, Inc. – informacije
Glavni izvršni direktor-
Zaposlenici21
Osnovano1980
SjedišteBasking Ridge, New Jersey, Sjedinjene Američke Države
Sektor-
Web-lokacijalisata.com